STOCK TITAN

Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Scribe Therapeutics (Nasdaq: SCTX) presented preclinical results for STX-1150 and STX-1200 at the American Heart Association Scientific Sessions 2026. A single dose of an STX-1150 prototype reduced LDL cholesterol by up to 68% in non-human primates. At a therapeutically relevant dose, LDL cholesterol stayed more than 50% lower for at least two years without permanent DNA modification. In a separate primate study, repeat dosing lowered LDL cholesterol further while maintaining tolerability. Scribe expects initial Phase 1 data for STX-1150 in the first half of 2027.

In non-human primates, one dose of an STX-1200 surrogate achieved more than 80% editing of the LPA gene in the liver and was associated with a more than 95% reduction in circulating apolipoprotein(a), a component of lipoprotein(a), at 10 weeks. Testing in human liver cells found no detectable off-target editing at the sites examined.

Loading...
Loading translation...
10 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointOne STX-1150 prototype dose lowered LDL cholesterol by up to 68% in non-human primates; lowering exceeded 50% for at least two years at a therapeutically relevant dose without permanent DNA modification
  • Moderate pointOne STX-1200 surrogate dose achieved more than 80% liver LPA editing, associated with a more than 95% drop in circulating apolipoprotein(a) at 10 weeks in non-human primates
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Initial STX-1150 Phase 1 data are expected in the first half of 2027 from the single ascending dose portion
  • Moderate pointRepeat STX-1150 dosing progressively lowered LDL cholesterol further in non-human primates while maintaining tolerability
  • Minor pointSTX-1150 toxicology study found no adverse findings related to the test article
5 minor points
  • Minor pointSTX-1150 testing detected no off-target changes
  • Minor pointSTX-1200 testing in primary human liver cells found no detectable off-target editing across more than 125 sites selected for testing
  • Minor pointSTX-1200 prototype lowered serum apolipoprotein(a) by more than 95% in a transgenic LPA mouse model after one dose below 0.5 mg/kg
  • Minor pointSTX-1150 potency was ≥2 to 5-fold greater in human translational models than in non-human primates
  • Minor pointCalifornia Institute for Regenerative Medicine grant supports continued development of STX-1200

Negative

  • None.

News Explained

Scribe reports STX-1150 is currently being evaluated in a first-in-human trial, placing the program in clinical testing.

Key Figures

Sustained LDL-C reduction: >50% for at least two years Maximum LDL-C reduction: Up to 68% Greater potency in human translational models: ≥2 to 5-fold +4 more
Sustained LDL-C reduction
>50% for at least two years
Single therapeutically relevant dose in non-human primates
Maximum LDL-C reduction
Up to 68%
STX-1150 prototype, single administration in non-human primates
Greater potency in human translational models
≥2 to 5-fold
Compared with non-human primates
Hepatic LPA editing
>80%
STX-1200 surrogate in non-human primates
Circulating plasma Apo(a) reduction
>95%
Associated with hepatic LPA editing at 10 weeks post-dose
Serum Apo(a) reduction
>95%
Single low dose (<0.5 mg/kg) in a transgenic LPA mouse model
Off-target sites assessed
>125 sites with no detectable off-target editing
Primary human hepatocytes

Historical Context

1 past event · Latest: Nov 04
1 event
  1. Nov 04

    AHA data preview

    24h Move
    +3.6%

    Previewed two-year STX-1150 LDL-C lowering and durable STX-1200 Lp(a) reduction for AHA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ldl-c, lp(a), single ascending dose, hepatocytes
4 terms
ldl-c medical
"achieved up to 68% LDL-C reductions in non-human primates"
LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.
lp(a) medical
"durably lower circulating Lp(a)"
Lp(a), or lipoprotein(a), is a blood particle that carries cholesterol and a specific protein; think of it as a delivery truck that can drop off harmful cargo along artery walls. High Lp(a) levels are linked to increased risk of heart disease and stroke, so changes in testing, treatments, or clinical results for Lp(a) can affect healthcare costs, drug prospects, and investor expectations for companies working on cardiovascular diagnostics or therapies.
single ascending dose medical
"single ascending dose portion of its Phase 1 trial"
A single ascending dose is a method used in testing new medicines where small amounts are given to participants, gradually increasing each time to find the safest and most effective dose. For investors, it provides important information about a drug’s safety and potential, helping gauge the progress and prospects of a pharmaceutical development.
hepatocytes medical
"in primary human hepatocytes (PHHs)"
Hepatocytes are the main functional cells of the liver that act like factory workers, breaking down nutrients, producing important proteins, making bile to aid digestion, and clearing toxins and drugs from the blood. For investors, hepatocyte health and behavior matter because they determine liver function, influence drug safety and dosing, affect outcomes in liver disease markets, and play a central role in regulatory drug testing and approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C lowering while maintaining tolerability

STX-1200 surrogate achieved >95% Lp(a) reduction in non-human primates, without detectable off-target editing in primary human hepatocytes, reinforcing the potential for a potent and precise one-time Lp(a)-lowering therapy designed to recapitulate genetic protection of low Lp(a)

Results reinforce Scribe’s approach to addressing a critical unmet need in cardiovascular care: ultra-long-acting therapies designed to sustainably and substantially lower atherogenic lipoproteins and empower patients to prevent disease before it develops

ALAMEDA, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, reported updated preclinical data from its STX-1150 and STX-1200 programs at the American Heart Association (AHA) Scientific Sessions 2026. The findings bolster Scribe’s strategy to develop ultra-long-acting genetic medicines targeting key lipid drivers of atherosclerotic cardiovascular disease (ASCVD).

Cardiovascular risk accumulates over decades of exposure to elevated atherogenic lipids, making early and sustained lipid lowering critical. The efficacy of existing LDL-C-lowering therapies depends on lifelong treatment persistence, but 50 to 70% of patients discontinue certain therapies within one year. Meanwhile, about one in five people have genetically elevated Lp(a), an independent and causal ASCVD risk factor with no approved therapies. Scribe's STX-1150 and STX-1200 programs aim to address these challenges by translating the protective effects of naturally occurring human genetic variants into durable genetic medicines.

“We believe that a majority of heart attacks could be prevented if patients and providers were able to proactively, easily, and sustainably reduce lipids that drive ASCVD,” said Benjamin L. Oakes, Ph.D., co-founder and CEO of Scribe Therapeutics. “Our AHA data reinforce the potential for purpose-built CRISPR medicines to transform chronic cholesterol management and bring us closer to our vision of making the protective benefits of human genetics accessible to millions of patients.”

STX-1150: Epigenetic silencer sustains >50% LDL-C lowering for at least two years after a single therapeutically relevant dose

STX-1150 is Scribe’s lead investigational CRISPR-based epigenetic silencing therapy, currently being evaluated in a first-in-human trial in adults with elevated LDL-C and increased cardiovascular risk. Utilizing Scribe's proprietary Epigenetic Long-term X-Repressor (ELXR) technology, STX-1150 is designed to recapitulate the cardioprotective biology of individuals with naturally occurring PCSK9 loss-of-function variants by durably repressing PCSK9 transcription without cutting or permanently altering DNA.

In a late-breaking presentation at AHA, Scribe reported that:

  • A single administration of a STX-1150 prototype achieved up to 68% LDL-C reductions in non-human primates (NHPs), with >50% lowering sustained for two years at a therapeutically relevant dose.
  • No off-target changes were detected and a GLP toxicology study identified no test-article-related adverse findings.
  • STX-1150 showed ≥2 to 5-fold greater potency in human translational models compared to NHPs, supporting the potential for effective translation.
  • In an additional NHP study, re-dosing of STX-1150 enabled progressively greater LDL-C lowering while maintaining tolerability.

The findings demonstrate the potential for years of sustained LDL-C lowering from a single treatment with substantially reduced dosing burden compared with current therapies, while supporting the potential for repeat dosing. As previously announced, Scribe anticipates reporting initial clinical data from the single ascending dose portion of its Phase 1 trial of STX-1150 in the first half of 2027.

STX-1200: Gene editor achieves saturating liver editing and >95% Lp(a) reduction in non-human primates with a single administration

STX-1200 is an investigational CRISPR-CasX gene editing therapy designed to inactivate the LPA gene in hepatocytes through a single administration to durably lower circulating Lp(a). By reducing production of apolipoprotein(a) [Apo(a)], a key component of Lp(a), STX-1200 aims to recapitulate the protective biology of naturally occurring LPA-lowering variants.

At AHA 2026, Scribe presented preclinical data demonstrating:

  • A single administration of a STX-1200 surrogate achieved >80% hepatic LPA editing, associated with >95% reduction in circulating plasma Apo(a) at 10 weeks post-dose.
  • A STX-1200 prototype achieved >95% serum Apo(a) reduction from a single low dose (<0.5 mg/kg) in a pharmacologically relevant transgenic LPA mouse model.
  • No detectable off-target editing was observed across >125 nominated sites in primary human hepatocytes (PHHs), even at supersaturating doses.

Taken together, the data support the potential for potent and precise Lp(a) lowering from a one-time treatment that aims to recapitulate the genetic protection of LPA-lowering variants. Continued development of STX-1200 is supported by a grant from the California Institute for Regenerative Medicine (CIRM).

About Scribe Therapeutics Inc.

Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature's blueprint for improved cardiovascular health, Scribe's initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The Company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe’s strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe’s product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, and other programs; the potential for translation of STX-1150’s preclinical potency findings to humans and the potential for repeat dosing; and the expected use and benefits of CIRM funding are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the risk that results of preclinical studies may not be predictive of results in clinical trials; the risk that the durability, potency and tolerability observed in preclinical models may not translate to humans; the risk that Scribe’s product candidates may cause undesirable side effects; and those described under the heading “Risk Factors” in Scribe’s filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events.

Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com

Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How long did Scribe Therapeutics' STX-1150 prototype lower LDL cholesterol after one dose?

At a therapeutically relevant dose, the STX-1150 prototype kept LDL cholesterol more than 50% lower for at least two years in non-human primates. The prototype achieved LDL cholesterol reductions of up to 68% after a single administration.

What did Scribe Therapeutics' STX-1200 surrogate achieve in non-human primates?

A single dose achieved more than 80% editing of the LPA gene in the liver, which was associated with a more than 95% reduction in circulating apolipoprotein(a) at 10 weeks after dosing.

Who is being studied in Scribe Therapeutics' first human trial of STX-1150?

The first-in-human trial is evaluating STX-1150 in adults with elevated LDL cholesterol and increased cardiovascular risk.

How broadly did Scribe Therapeutics test STX-1200 for off-target editing in human liver cells?

The testing found no detectable off-target editing at more than 125 sites selected for testing in primary human liver cells, even at doses above the level needed to reach saturation.

Keep reading